Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
RemeGen Co., Ltd. clinical trials
The registry lists 80 studies whose lead sponsor is RemeGen Co., Ltd.. 39 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Keep track of what changes. Save the RemeGen Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to RemeGen Co., Ltd..
- RemeGen Co., Ltd.80 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 80. Browse all 80 →
- Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT07874282Phase 2
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingNCT04400695Phase 3
- A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid TumorsRecruitingNCT07537881Phase 1/2
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingNCT07829549Phase 3
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Phase 3
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal CancerRecruitingNCT07462143Phase 2/3
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseaseNot yet recruitingNCT07495033Phase 3
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingNCT07249632Phase 3
- A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid TumorsRecruitingNCT07105215Phase 1/2
- DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerRecruitingNCT06178159Phase 2
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Phase 2
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
- Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerRecruitingNCT06642545Phase 2
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT06038396Phase 1/2
- A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingNCT05205850Phase 1/2
- A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingNCT06016062Phase 1/2
- A Study of Telitacicept in Lupus NephritisRecruitingNCT05680480Phase 2
- A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy SubjectsRecruitingNCT06549959Phase 1
- To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RecruitingNCT06378242Phase 1/2
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingNCT06389006Phase 2
- Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerRecruitingNCT06227156Phase 2
- A Study of RC88 Combined With Sintilimab for Advanced Solid TumoursRecruitingNCT05804526Phase 1/2
- RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLCRecruitingNCT05821933Phase 1/2
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
- Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingNCT06227117Phase 2
- A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
- A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT05297552Phase 2
- A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)RecruitingNCT05135715Phase 2
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingNCT04714190Phase 3
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)RecruitingNCT05514158Phase 1
- A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesRecruitingNCT04965519Phase 2
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaRecruitingNCT05302284Phase 3
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Phase 2
- RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 ExpressionRecruitingNCT05940896Phase 1
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaRecruitingNCT05885503Phase 3
- Efficacy and Safety of RC28-E Versus AfliberceptRecruitingNCT05727397Phase 3
- RC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsRecruitingNCT05943379Phase 2
- A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromeCompletedNCT04078386Phase 2
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Phase 2
- A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum DisordersTerminatedNCT03330418Phase 3
- RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II TrialTerminatedNCT04625153Phase 2
- A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus ErythematosusCompletedNCT05687526Phase 1
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Phase 1
- RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerCompletedNCT06173037Phase 2
- A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid TumorsCompletedNCT04175847Phase 1/2
- A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsCompletedNCT04617314Phase 1
- A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant TumorCompletedNCT05628857Phase 2
- A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursCompletedNCT05508334Phase 1/2